What we do
Built, bought or rescued.
Therapeutic areas: oncology, rare tumours and rare diseases, biosimilars, and specialty pharma.
Deals and cross-border growth
A deal succeeds when three things are right: the partner, the product, and the terms that let you realise the value. We help you get all three right, and we stay with you from the first search to execution after signing. More than 50 deals since 2008.
02Scaling and turnaround
Building a business from zero, scaling it and turning it around when it stops growing are three different jobs. Each needs its own strategy and a team that can deliver it. We have done all three: from the first hire to a €656M exit, from €1.4B to €2.0B through partnerships, launches and market access, and from a written-off brand to a blockbuster.
03Board and CEO advisory
We help boards and CEOs shape how the company grows, organically and through deals: whether to change the business model or the go-to-market, where the synergies really are, and how to reshape the business to capture them. We have put these choices to an executive board ourselves. We work as board members, as a sounding board or as fractional executives.
Track record
Built, bought and run, from the inside.
€1.4B to €2.0B
Global oncology franchise P&L, 2021 to 2026
€656M
Biosimilars business founded and exited
$3.4B
Acquisition, initiated and co-led
Three times
A founder
Ten years
Leading global oncology, with P&L
50+
Deals, 2008 to 2026
70+
Due diligences, most of them led
300+
Companies assessed for partnering, investment and M&A
2008 to 2026: publicly announced deals and partnerships Yariv started, negotiated, sponsored or oversaw, in thirteen countries.
Record · 2008 to 2026
Thirteen countries
Americas, Europe and Asia
Select a country to filter the tableTap a country to filter the table
These deals were announced publicly. Many of their terms, and further agreements, were never disclosed.
The full record, public and confidential.
An agreement can count in more than one category.
We see growth where others see decline, and help your team deliver it.
Yariv Hefez, Founder
Newsletter · from Accumulating Impact
Impact Notes.
A monthly letter. One piece, no noise.
Each month, we write one piece on building, buying and rescuing life sciences businesses: what moved in the market, the decision behind a deal, and what it changed. It is the same thinking published on this site, sent to your inbox first.
Almost there. Check your inbox and confirm your address.
A short welcome note arrives once you confirm. After that, one letter at the end of each month, and nothing in between.
Read the last one →That address doesn't look complete. Check it and try again.
Something failed on our side, not yours. Try again, or write to info@accumulatingimpact.com.
One email a month. Unsubscribe in one click.
Contact
Bring us the ambition.
A thirty-minute conversation about the business you want to build, buy or turn around. No deck, no pitch.
Prefer email? info@accumulatingimpact.com Address copied
